A Phase 3 interventional study of VBI-S in Septic Shock, Sepsis and Hypovolemia, sponsored by Vivacelle Bio. Completed at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.
Sponsored by Vivacelle Bio · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 164 studies in Shock, Septic with a site in United States — 18 open to participants now, 26 under way, 1 of them phase 3. Shock, Septic · United States.
Among the 164 studies in Shock, Septic with a site in United States, this one is the 67th largest by enrollment of the 116 interventional ones that give a count, is one of 6 that started in 2024, is one of 12 in phase 3, and was the 145th registered.
1,084 studies on the registry are indexed under Shock, Septic; 236 are open to participants now.
Browse Shock, Septic studies →18 of the 164 studies in Shock, Septic with a site in United States are open now. Recruiting first, the newest first:
Intermountain Health Care, Inc. · Sites in United States
Ages 18+
Mayo Clinic · Sites in United States
Ages 18+
University of Pennsylvania · Sites in United States
Ages 18–80
The Cleveland Clinic · Sites in United States
Ages 18+
Brett A Faine · Sites in United States
Ages 18–99
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 137 Shock, Septic studies recruiting now, 103 (75%) set no upper age limit and 18 (13%) stop at 75 or younger; 11 take children under 18; 14 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
164 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 19 · Phase 2 38 · Phase 3 17 · Phase 4 15
First in 1992; this study’s year is marked. 6 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 39 is below the median of 78 across 639 interventional studies indexed under Shock, Septic.
Median enrollment 50 across the 116 interventional studies, 330 across the 47 observational. Of the 110 that completed or were terminated, 47 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 164 have an industry lead sponsor. The 10 most frequent:
Vivacelle Bio is the lead sponsor of 2 studies on the registry; none are open to participants now.
Vivacelle Bio has 2 studies filed under Shock, Septic — fewer than ten, so there is no comparison to draw.
11 of the studies in Shock, Septic with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01315782The University of Texas Health Science Center, HoustonAlveolar Dead Space as Predictor of Organ Failure in Severe Sepsis | 2026-12 |
| NCT07425587Bluejay Diagnostics, Inc.Multicenter Symphony™ IL-6 Monitoring Sepsis ED Pilot Study | 2026-12-30 |
| NCT06654895Bluejay Diagnostics, Inc.Multicenter Symphony IL-6 Monitoring Sepsis ICU Validation Study | 2026-12-31 |
| NCT05011656ExThera Medical CorporationBlood Purification for the Treatment of Pathogen Associated Shock | 2026-12-31 |
| NCT06693726Brett A FaineEarly Angiotensin II in the Emergency Department | 2026-12-31 |
Add all 11 to your calendar (.ics) → With an account.
Among the 164 studies in Shock, Septic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is being conducted to evaluate the safety and effectiveness of VBI-S in elevating the blood pressure of septic shock patients with absolute or relative hypovolemia.
PURPOSE OF THE STUDY This study is being conducted to evaluate the safety and effectiveness of VBI-S in elevating the blood pressure of septic shock patients with absolute or relative hypovolemia.
STUDY TREATMENT Sepsis is a serious condition resulting from the presence of harmful microorganisms in the blood or other tissues and the body's response to their presence, leading to the malfunctioning of various organs. When hypotension due to sepsis cannot be reversed with the infusion of fluids the patient is in a state of septic shock. Septic shock is therefore an acute medical emergency and delayed therapy can lead to organ injury. VBI-S is intended to raise blood pressure in patients with septic shock.
Randomization and blinding: This is a randomized, controlled, open-label study and blinding is not applicable to this study.
Data Safety Monitoring Board: A Data Safety Monitoring Board (DSMB) will review the study data.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Sepsis diagnosis: The presence of infection which can be proven or suspected by 2 or more of the following criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Treatment with VBI-S
Drug: VBI-S
VBI-S is made of small particles of specific lipids called micelles and liposomes for the treatment of hypotension.
Elevation in Average Mean Arterial Pressure
The primary endpoint is defined as an elevation in average mean arterial pressure by at least 10 mmHg from baseline within 3 hours of initiation of study treatment on Day 1
Time frame: 12 months
Dose of Pressor Drugs
The number of patients in whom the dose of pressor drugs could be decreased after infusion of VBI-S to maintain a mean arterial pressure of 60-65 mmHg.
Time frame: 12 months
Sequential Organ Failure Assessment (SOFA) Score
Change in Sequential Organ Failure Assessment (SOFA) Score on a scale of 0 to 24. A higher score indicates a worse outcome.
Time frame: 12 months
Ratio of Arterial Partial Pressure of Oxygen/Fraction of Inspired Oxygen
Change in ratio of partial pressure of oxygen in arterial blood/Fraction of inspired oxygen (P/F ratio).
Time frame: 12 months
Arterial Oxygen Saturation
Change in arterial oxygen saturation.
Time frame: 12 months
Partial Pressure of Oxygen
Change in partial pressure of oxygen.
Time frame: 12 months
Serum Procalcitonin
Change in serum procalcitonin
Time frame: 12 months
Serum Creatinine
Change serum creatinine
Time frame: 12 months
Post-treatment Survival
Change in post-treatment survival
Time frame: 12 months
Adverse Drug Reactions
The number and proportion (%) of patients with treatment-emergent adverse drug reactions.
Time frame: 12 months
Plan to share: No
No publications or documents are linked to this record.
Ran from Aug 2024 to primary completion in Jun 2026, 22 months.
Of 46 phase 3 interventional studies under Shock, Septic, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 59. This study's 22 months is below that.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 26, 2026: primary completion Dec 2025 → Jun 2026 and completion Dec 2025 → Jun 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Vivacelle Bio